Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

0.2710 +0.0065 (+2.46%)
Official Closing Price Updated: 8:00 PM EDT, Jun 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,375,119
Open 0.2900
Bid (Size) 0.2675 (917)
Ask (Size) 0.2797 (13)
Prev. Close 0.2645
Today's Range 0.2581 - 0.2900
52wk Range 0.2475 - 0.7380
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CYBN Stock Earnings: Cybin Beats EPS for Q4 2023
CYBN stock results show that Cybin beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development
Explore Cybin Inc.'s FY 2024 results: $78M loss and strides in psychedelic therapy for mental health. Read now! 
Via Benzinga

Performance

YTD
-32.25%
-32.25%
1 Month
-22.46%
-22.46%
3 Month
-36.10%
-36.10%
6 Month
-33.90%
-33.90%
1 Year
-26.36%
-26.36%

More News

Read More
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Releases FY Financial Report, Business Update
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO Featured Presenter at Upcoming H.C. Wainwright Neuro Perspectives Virtual Conference
Via Investor Brand Network
Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From Cybin Inc.
Via Business Wire
Latest Executive Cannabis Changes You Should Know About: Curaleaf, Planet 13 Elect Directors And More
Via Benzinga
Topics Cannabis
Exposures Cannabis
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Strategic Appointment of Dr. Atul Mahableshwarkar
Via Investor Brand Network
Exposures Product Safety
Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development
From Cybin Inc.
Via Business Wire
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
Via Benzinga
Exposures Product Safety
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation at Interdisciplinary Conference on Psychedelic Research 2024
Via Investor Brand Network
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024
From Cybin Inc.
Via Business Wire
BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO Slated to Present at Upcoming Alliance Global Partners Healthcare Company Showcase
Via Investor Brand Network
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
From Cybin Inc.
Via Business Wire
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
Via Benzinga
Topics Cannabis
Exposures Cannabis
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Issues Corporate Update, Eyes Runway for Upcoming Clinical Milestones
Via Investor Brand Network
Exposures Product Safety
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation at the 27th Annual Milken Institute Global Conference
Via Investor Brand Network
Exposures Product Safety
Cybin to Participate at the 27th Annual Milken Institute Global Conference
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Research Published in “Journal of Medicinal Chemistry”
Via Investor Brand Network
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Receives Notice of Patent Grant for CYB003 Breakthrough MDD Therapy Program
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Present at Bloom Burton & Co. Healthcare Conference
Via Investor Brand Network
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Cybin Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.